Guy A. Young, MD

Professor of Pediatrics (Clinical Scholar)

Image of Guy A. Young, MD
Is this your profile? Click to edit

Overview

Following medical school, I completed my residency in pediatrics at Schneider Children’s Hospital-Long Island Jewish Medical Center which is part of the Albert Einstein College of Medicine. I then completed a fellowship in pediatric hematology/oncology at Children’s National Medical Center in Washington, DC which is part of the George Washington University School of Medicine. I then began my research career at the Children’s Hospital of Orange County under the mentorship of Dr. Diane Nugent. There, I became interested in improving the treatment for patients with hemophilia and inhibitors and for children with blood clots. I received my first independent grants there inculding a grant from the FDA to study a new anticoagulant in children. In addition, I became interested in thromboelastography. In 2007, I moved the Children’s Hospital Los Angeles where I am continuing to perform research in the same areas as I had started in Orange County.

Awards

  • National Hemophilia Foundation: Physician of the Year, 2013

Research Funding

  • Dose-finding, pharmacokinetic, safety and efficacy of bivalirudin in children
    NIH · R01HL095110 · Sep 26, 2008 – Jan 31, 2013 · Role: Principal Investigator
  • FONDAPARINUM IN CHILDREN WITH THROMBOSIS
    NIH · R01FD003091 · Sep 20, 2006 – May 31, 2009 · Role: Principal Investigator

Publications

  • Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation. J Thromb Haemost. 2020 07; 18(7):1672-1685.. View in PubMed
  • The Edoxaban Hokusai VTE PEDIATRICS Study: An open-label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease. Res Pract Thromb Haemost. 2020 Jul; 4(5):886-892.. View in PubMed
  • FondaKIDS III: A long-term retrospective cohort study of fondaparinux for treatment of venous thromboembolism in children. Pediatr Blood Cancer. 2020 08; 67(8):e28295.. View in PubMed
  • Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study. Haemophilia. 2020 May; 26(3):494-502.. View in PubMed
  • Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigms. Expert Rev Hematol. 2020 04; 13(4):313-321.. View in PubMed
  • Peripherally inserted central catheters lead to a high risk of venous thromboembolism in children. Blood. 2020 01 16; 135(3):220-226.. View in PubMed
  • Comparative validation study of risk assessment models for pediatric hospital-acquired venous thromboembolism. J Thromb Haemost. 2020 03; 18(3):633-641.. View in PubMed
  • A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019 12 12; 134(24):2127-2138.. View in PubMed
  • Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. Blood. 2019 11 28; 134(22):1973-1982.. View in PubMed
  • Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol. 2020 Jan; 7(1):e18-e27.. View in PubMed